TS
AZN icon

Thomas Steyer’s AstraZeneca AZN Stock Holding History

Thomas Steyer’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$109M Buy
574,000
+347,501
+153% +$65.4M 0.5% 33
2026
Q1 		$44.7M Buy
+226,499
New +$43.7M 0.23% 44
2024
Q3 		– Sell
-1,204,859
Closed -$188M – 167
2024
Q2 		$188M Buy
1,204,859
+475,000
+65% +$71.5M 0.81% 38
2024
Q1 		$98.9M Sell
729,859
-1,182,287
-62% -$157M 0.42% 44
2023
Q4 		$258M Sell
1,912,146
-1,117,631
-37% -$145M 1.18% 28
2023
Q3 		$410M Hold
3,029,777
– – 1.91% 16
2023
Q2 		$434M Buy
3,029,777
+96,000
+3% +$14.1M 2.18% 12
2023
Q1 		$407M Sell
2,933,777
-4,454
-0.2% -$599K 2.22% 12
2022
Q4 		$398M Buy
2,938,231
+145,750
+5% +$18.3M 2.35% 10
2022
Q3 		$306M Buy
2,792,481
+477,500
+21% +$60.6M 1.68% 15
2022
Q2 		$306M Buy
2,314,981
+526,889
+29% +$69.1M 1.66% 17
2022
Q1 		$237M Buy
1,788,092
+835,014
+88% +$100M 1.15% 32
2021
Q4 		$111M Buy
953,078
+786,078
+471% +$92.5M 0.55% 46
2021
Q3 		$20.1M Buy
+167,000
New +$19.4M 0.09% 101
2019
Q4 		– Sell
-1,187,893
Closed -$106M – 118
2019
Q3 		$106M Sell
1,187,893
-862,107
-42% -$74.8M 0.8% 31
2019
Q2 		$169M Buy
2,050,000
+107,500
+6% +$8.43M 1.1% 25
2019
Q1 		$157M Hold
1,942,500
– – 1.18% 27
2018
Q4 		$148M Buy
1,942,500
+232,500
+14% +$18.2M 1.08% 29
2018
Q3 		$135M Sell
1,710,000
-215,000
-11% -$16.3M 0.8% 31
2018
Q2 		$135M Buy
1,925,000
+142,500
+8% +$10.3M 0.83% 30
2018
Q1 		$125M Sell
1,782,500
-100,000
-5% -$6.93M 0.86% 33
2017
Q4 		$131M Buy
1,882,500
+292,500
+18% +$19.7M 1.06% 28
2017
Q3 		$108M Buy
1,590,000
+1,302,500
+453% +$82.3M 0.96% 28
2017
Q2 		$19.6M Sell
287,500
-288,750
-50% -$18.9M 0.2% 55
2017
Q1 		$35.9M Buy
576,250
+393,750
+216% +$22.9M 0.39% 43
2016
Q4 		$9.97M Buy
+182,500
New +$10.4M 0.11% 56

Other funds holding AZN

EP
Evelyn Partners London $46.9B AUM
IA
Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Thomas Steyer's AZN Position: Q2 2026 in Review

Thomas Steyer increased its AstraZeneca (AZN) stake by 153% in Q2 2026, buying an estimated $65.4M and bringing the position to 574,000 shares worth $109M. The position accounts for 0.5% of the portfolio, ranked #33.

Thomas Steyer first reported a position in AZN in Q4 2016 and has held it in 26 quarters since. The position peaked at $434M in Q2 2023. 1,495 funds tracked by Wall St. Rank hold AZN as of Q2 2026.

  • Thomas Steyer held 574,000 shares of AstraZeneca worth $109M as of Q2 2026.
  • Thomas Steyer bought 347,501 AstraZeneca shares in Q2 2026, an estimated $65.4M.
  • AstraZeneca made up 0.5% of Thomas Steyer's portfolio in Q2 2026, its #33 holding.
  • Thomas Steyer first reported a position in AstraZeneca in Q4 2016 and has held it in 26 quarters since.
  • Thomas Steyer's AstraZeneca position peaked at $434M in Q2 2023.
  • 1,495 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.

Based on Farallon Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.